Arrowhead Research Corporation (now identified in the request as Arrowhead Pharmaceuticals, Inc.) — Form 10-Q Summary
Reporting period: Fiscal first quarter ended December 31, 2015. The filing is for Arrowhead Research Corporation and presents unaudited consolidated results. The company develops RNA interference (RNAi)-based therapeutics and was advancing clinical and preclinical drug candidates.
Financial performance and liquidity
| Metric | Quarter ended Dec. 31, 2015 | Prior-year quarter |
|---|---|---|
| Revenue | $43,750 | $170,750 |
| Operating expenses | $19.4 million | $25.3 million |
| Operating loss | $19.3 million | $25.1 million |
| Net loss | $19.3 million | $22.6 million |
| Basic and diluted loss per share | $0.32 | $0.41 |
| Cash used in operating activities | $21.1 million | $24.2 million |
- At December 31, 2015, cash and cash equivalents were $62.2 million and short-term investments were $14.4 million, compared with $81.2 million and $17.5 million, respectively, at September 30, 2015. Total assets were $111.4 million.
- Cash declined by $19.0 million during the quarter. Investing activities provided $2.6 million, primarily from $3.0 million of investment maturities, partly offset by $0.4 million of capital spending. Financing activities used about $0.5 million, mainly for taxes on net-settled restricted stock units.
- Current assets were $82.3 million and current liabilities were $12.3 million. The filing reports capital lease obligations of about $0.7 million and contingent consideration obligations of $5.9 million; it does not report conventional borrowings in the presented balance sheet.
- Gross margin is not meaningful for this development-stage business: revenue was minimal and the filing reports operating expenses rather than cost of revenue. No operating margin is reported.
Changes versus the prior-year quarter
- Revenue fell about 74%, primarily because the prior-year period included collaboration and materials-study revenue.
- Operating expenses decreased about 23%, principally because ARC-520 manufacturing costs declined as the Phase 2b manufacturing campaign neared completion. R&D expense fell 42% to $10.3 million.
- Management cautioned that clinical-trial costs may rise as ARC-520 enrollment expands and other candidates advance. Salaries and payroll-related costs increased 24%, while depreciation and amortization rose to $0.8 million, partly reflecting amortization of assets acquired from Novartis.
- Net loss improved about 15%; the prior-year quarter included $2.4 million of income from changes in derivative values, compared with a small net derivative loss in the current quarter.
Outlook, developments, and risks
- Management said existing financial resources were expected to fund operations for at least the next 12 months. This is management’s estimate, not a guarantee; the business expects continued substantial investment in R&D, clinical trials, and drug manufacturing.
- ARC-520 Phase 2 studies continued. The company reported reductions in hepatitis B surface antigen in a Phase 2a study and said it began dosing the first patient in a Phase 2b combination study in January 2016. ARC-AAT patient dosing began in an ongoing Phase 1 study; the company also described progress on additional preclinical candidates.
- Future commitments for drug manufacturing, toxicology, and clinical studies were approximately $47.5 million, including $25.2 million expected in the remainder of fiscal 2016. Additional technology-license milestone payments could reach the mid-to-upper tens of millions of dollars, with royalties under certain agreements.
- In January 2016, the company signed a 10-year lease for a larger Madison research facility. Base lease payments are expected to total approximately $15.4 million; first-year taxes and operating costs were estimated at $0.9 million, and leasehold improvements at $7.3 million net of tenant allowances.
- The company disclosed securities class-action and shareholder derivative litigation relating to statements about hepatitis B research, as well as a separate dispute concerning a Rice University license. It recorded no liability, stated that it intended to defend the matters, and did not expect them to materially affect the financial statements.
- Clinical, regulatory, manufacturing, financing, intellectual-property, and litigation risks remain material. The filing stated there had been no material changes to the risk factors in its prior Form 10-K.
Important facts for investors to verify
- Whether cash burn and clinical/manufacturing spending remain consistent with management’s stated 12-month liquidity outlook.
- Enrollment, safety, efficacy, and regulatory progress for ARC-520 and ARC-AAT, and the resulting timing and cost of trials.
- Whether the $47.5 million in purchase commitments, future license milestones, and the new facility’s costs affect available liquidity more than anticipated.
- Developments in the disclosed litigation and whether any liability or material financial impact becomes probable and estimable.
- The filing’s company name is Arrowhead Research Corporation; confirm the issuer identity when matching it to the requested company and security.